AIC, Anomalous Insoluable Complexes, Assumptions on Treatment? | Deep Dive #1

Clinical Analysis of Anomalous Insoluble Complexes (AIC) and Fibrinaloid MicroclotsExecutive SummaryThe identification of Anomalous Insoluble Complexes (AIC), also known as fibrinaloid microclots or "white clots," represents a critical shift in vascular pathology. Unlike traditional "red clots," which are primarily composed of red blood cells trapped in a loose fibrin mesh, AICs are characterized by a dense, matted, amyloid-rich ultrastructure. These structures demonstrate extraordinary resistance to the body's natural fibrinolytic systems and traditional pharmacological interventions.Evidence suggests these clots are triggered by exogenous inflammagens—notably the SARS-CoV-2 spike protein and bacterial components—which catalyze the misfolding of fibrinogen into a β-sheet secondary structure. Emerging research, including proteinomic and histological analysis, confirms that these clots often form during active blood flow while a patient is alive, potentially leading to systemic microvascular obstruction, chronic hypoxia, and organ failure. Therapeutic strategies focus on Systemic Enzyme Therapy (SET) using proteases like nattokinase and serrapeptase, redox modulation via N-Acetylcysteine (NAC), and various phytochemical interventions to bypass stalled endogenous degradation pathways.